Search for: "State v. Sandoz" Results 1 - 20 of 416
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
21 Jun 2016, 3:12 pm by Patent Docs
Sandoz (No. 15-1195) appeals to express the views of the United States. [read post]
14 Mar 2022, 10:13 pm by Jackie O'Brien (AU)
The post Lundbeck v Sandoz – High Court decision appeared first on The Brand Protection Blog. [read post]
The post Lundbeck v Sandoz – High Court decision appeared first on Health Law Pulse. [read post]
14 Mar 2022, 10:13 pm by Jackie O'Brien (AU)
The post Lundbeck v Sandoz – High Court decision appeared first on The Brand Protection Blog. [read post]
22 Dec 2022, 3:15 pm by Lawrence B. Ebert
’s (collectively, “Sandoz’s”) generic product would not induce infringement of the LFT patents, and (3) sale of Sandoz’s generic product would not directly infringe Genentech’s Drug-Drug Interaction (“DDI”) patents.2 See Genentech, Inc. v. [read post]
26 Apr 2017, 9:59 pm by Patent Docs
By Andrew Williams -- Earlier today, the Supreme Court heard oral arguments in Sandoz Inc. v. [read post]
12 Feb 2015, 11:27 am by Lawrence B. Ebert
The SupremeCourt recently observed this challenge to patent claiminterpretation, stating in Nautilus, Inc. v. [read post]
3 Nov 2023, 7:15 am by David Hemming (Bristows)
The starting point for Mellor J’s analysis was Kitchin LJ’s judgment in Regeneron v Genentech [2013] EWCA Civ 93. [read post]
27 Jun 2014, 12:54 pm by Jason Rantanen
By Jason Rantanen Teva recently filed its merits brief in Teva v. [read post]
18 Nov 2009, 9:33 am
Unfortunately, this is not what Sandoz did. [read post]
3 Oct 2014, 8:58 am by Lisa Larrimore Ouellette
On October 15, the Supreme Court will hear arguments in Teva v. [read post]